Table_3.xls (9.5 kB)

Cardio-vascular risk factors, treatment and disease characteristics in the HIV− and HIV+ groups.

Download (0 kB)
dataset
posted on 19.04.2013, 01:56 by Lucette A. Cysique, Kirsten Moffat, Danielle M. Moore, Tammy A. Lane, Nicholas W. S. Davies, Andrew Carr, Bruce J. Brew, Caroline Rae
1

Atrial fibrillation, Myocardial infarction, congestive heart failure, peripheral arteriosclerosis, carotid/coronary arteriosclerosis.

2

This information was specifically part of the D.A.D. score and was entered as “yes” vs “no” for Abacavir and as the duration in months for Lopinavir/Ritonavir and Indinavir.

Note that there was a strong correlation between the Framingham score and the D.A.D. score in the HIV+ group (r = .67; p<.0001). There was moderate correlations between the Framingham score and the Augmentation Index (r = .31; p<.005) and the D.A.D. score and the Augmentation Index (r = .38; p<.004).

Standard assays for Cholesterol, Reference Intervals: 0.0–6.0 mmol/L; Auto Chemistry (8382–9164).

Standard assays for HDL Cholesterol, Reference Intervals: >1.0 mmol/L; Auto Chemistry (8382–9164).

Standard assays for High-sensitivity C Reactive Protein(hs-CRP), Reference Intervals: <10 mg/L; Auto Immunoassay (8382–9161).

History

Licence

Exports